CR10866A - Derivados de aril sulfamida y metodos para su uso - Google Patents

Derivados de aril sulfamida y metodos para su uso

Info

Publication number
CR10866A
CR10866A CR10866A CR10866A CR10866A CR 10866 A CR10866 A CR 10866A CR 10866 A CR10866 A CR 10866A CR 10866 A CR10866 A CR 10866A CR 10866 A CR10866 A CR 10866A
Authority
CR
Costa Rica
Prior art keywords
methods
aril
derivatives
sulfamide derivatives
tautomer
Prior art date
Application number
CR10866A
Other languages
English (en)
Inventor
Comas Casy Cameron Mac
Stephen Todd Cohn
Matthew L Crawley
Andrew Fensome
Joel Adam Goldberg
Douglas John Jenkins
Caflain Youghee Kim
Paige Erin Mahaney
Charles William Mann
Michael Anthony Marella
David John O'neill
Joseph P Sabatucci
Eugene Anthony Terefenko
Eugene John Trybulski
An Thien Vu
Richard Page Woodworth
Puwen Zhang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10866A publication Critical patent/CR10866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion se dirige a derivados de aril sulfamida de la formula I: o una sal farmaceuticamente aceptable, estereoisomero o tautomero de estos, que son inhibidores de recaptacion de monoamina, composiciones que contienen estos derivados, y metodos para su uso para la prevencion y tratamiento de afecciones, que incluyen, inter alia, sintomas vasomotrices, disfuncion sexual, trastornos gastrointestinales y trastorno genitourinario, trastornos depresivos.
CR10866A 2006-12-12 2009-06-12 Derivados de aril sulfamida y metodos para su uso CR10866A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86964406P 2006-12-12 2006-12-12

Publications (1)

Publication Number Publication Date
CR10866A true CR10866A (es) 2009-07-14

Family

ID=39273293

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10866A CR10866A (es) 2006-12-12 2009-06-12 Derivados de aril sulfamida y metodos para su uso

Country Status (20)

Country Link
US (4) US7601722B2 (es)
EP (1) EP2061776A1 (es)
JP (1) JP2010512401A (es)
KR (1) KR20090087506A (es)
CN (1) CN101600701A (es)
AR (1) AR064318A1 (es)
AU (1) AU2007333593A1 (es)
BR (1) BRPI0720289A2 (es)
CA (1) CA2671844A1 (es)
CL (1) CL2007003590A1 (es)
CR (1) CR10866A (es)
EC (1) ECSP099411A (es)
MX (1) MX2009006359A (es)
NO (1) NO20092092L (es)
PE (1) PE20081395A1 (es)
RU (1) RU2009121017A (es)
SV (1) SV2009003295A (es)
TW (1) TW200843753A (es)
WO (1) WO2008073459A1 (es)
ZA (1) ZA200904109B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156826A1 (en) * 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
CA2791672A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
DK2776387T3 (en) 2011-11-07 2017-05-08 Univ Emory Tricyclic amino containing compounds to treat or prevent symptoms associated with endocrine dysfunction
US9867813B2 (en) * 2015-11-17 2018-01-16 Thomas Daly Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
CN107337616A (zh) * 2017-07-13 2017-11-10 上海昕盛医药科技有限公司 一种盐酸班布特罗杂质f的合成方法
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
WO2019243523A1 (en) * 2018-06-21 2019-12-26 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
CN116003261A (zh) * 2022-12-19 2023-04-25 江苏康恒化工有限公司 新型聚氨酯扩链剂2-氨基-2’-氯二苯胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177221A (en) * 1963-02-05 1965-04-06 Mcneilab Inc 2, 1, 3-benzothiadiazoline-2, 2-dioxides
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
EP1309593B1 (en) * 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
RU2268883C2 (ru) * 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
EP1466625A4 (en) * 2001-12-28 2007-07-18 Takeda Pharmaceutical PREVENTIVE / HEALING MEDICINE FOR BLADDER DISORDER
WO2006114706A1 (en) 2005-04-26 2006-11-02 Pfizer Limited Triazole derivatives as vasopressin antagonists
TW200804325A (en) * 2005-09-29 2008-01-16 Wyeth Corp Benzothiadiazolylphenylalkylamine derivatives and methods of their use

Also Published As

Publication number Publication date
US20100029641A1 (en) 2010-02-04
MX2009006359A (es) 2009-06-26
US7601722B2 (en) 2009-10-13
ZA200904109B (en) 2010-04-28
AU2007333593A1 (en) 2008-06-19
US20080167303A1 (en) 2008-07-10
US20080161366A1 (en) 2008-07-03
WO2008073459A1 (en) 2008-06-19
JP2010512401A (ja) 2010-04-22
BRPI0720289A2 (pt) 2014-02-04
CA2671844A1 (en) 2008-06-19
ECSP099411A (es) 2009-07-31
SV2009003295A (es) 2009-10-29
NO20092092L (no) 2009-08-19
CN101600701A (zh) 2009-12-09
RU2009121017A (ru) 2011-01-20
TW200843753A (en) 2008-11-16
PE20081395A1 (es) 2008-09-17
US20080194654A1 (en) 2008-08-14
AR064318A1 (es) 2009-03-25
EP2061776A1 (en) 2009-05-27
KR20090087506A (ko) 2009-08-17
CL2007003590A1 (es) 2008-02-29

Similar Documents

Publication Publication Date Title
CR10866A (es) Derivados de aril sulfamida y metodos para su uso
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
PA8772701A1 (es) "COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO)-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA"
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA201270012A1 (ru) Сублингвальный апоморфин
WO2008036652A3 (en) Amidines as modulators of indoleamine 2,3-dioxygenase
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CR9331A (es) Inhibidores de vegf-r2 y metodos
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201170161A1 (ru) 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
EA201190293A1 (ru) Пролекарства триптолида
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)